ACE‑Inhibitor Use in Chronic Kidney Disease – Evidence‑Based Recommendations

Indications for Initiation

• Initiate ACE‑inhibitor therapy in patients with CKD stages G1‑G4 who have severely increased albuminuria (A3 ≥ 300 mg/g) and no diabetes. 1, 2
• Initiate ACE‑inhibitor therapy in patients with CKD stages G1‑G4 who have moderately‑to‑severely increased albuminuria (A2‑A3 ≥ 30 mg/g) and diabetes. 1, 2
• Consider ACE‑inhibitor therapy in patients with normal to mildly increased albuminuria (A1) when the drug is indicated for hypertension or heart failure with reduced ejection fraction. 1, 2

Initial Dosing and Titration

• Begin with low‑dose ACE‑inhibitors in patients who have heart failure, diabetes, or moderate CKD (eGFR 30‑60 mL/min/1.73 m²), then titrate gradually toward guideline‑recommended target doses. 3
• Titrate to the highest approved dose that the patient tolerates; clinical trials demonstrated that renoprotective and cardiovascular benefits are achieved at target doses rather than at lower maintenance doses. 1, 2

Laboratory Monitoring

• Measure serum creatinine and potassium 2–4 weeks after starting an ACE‑inhibitor or after any dose increase. 1, 2
• Perform periodic serum potassium monitoring in all patients with eGFR < 60 mL/min/1.73 m² who are receiving an ACE‑inhibitor. 4

Interpretation of Early Creatinine Changes

• An increase in serum creatinine of up to 30 % within the first 2–4 weeks reflects the intended hemodynamic effect (reduced intraglomerular pressure) and is associated with long‑term renoprotection, not acute kidney injury. 4
• Continue ACE‑inhibitor therapy unless the creatinine rise exceeds 30 % within 4 weeks of initiation or dose escalation; in that case, discontinue the drug. 1, 2, 4

Criteria for Dose Reduction or Discontinuation

• Reduce dose or stop the ACE‑inhibitor when eGFR falls < 15 mL/min/1.73 m² and the patient develops symptomatic hypotension, uncontrolled hyper‑kalemia despite treatment, or uremic symptoms. 1, 2
• Discontinue the ACE‑inhibitor for symptomatic hypotension that does not respond to volume optimization or diuretic dose reduction. 3, 5

Management of Hyper‑Kalemia and Drug Interactions

• Manage hyper‑kalemia with potassium‑lowering strategies (dietary restriction, diuretic optimization, sodium bicarbonate, gastrointestinal cation exchangers) rather than immediate ACE‑inhibitor cessation. 1, 2
• Stop potassium supplements and potassium‑sparing diuretics; avoid potassium‑based salt substitutes and high‑potassium foods. 3
• Avoid non‑steroidal anti‑inflammatory drugs (NSAIDs) because they increase hyper‑kalemia risk and blunt the compensatory renal plasma‑flow increase that accompanies ACE‑inhibition. 3

Continuation in Advanced CKD

• Maintain ACE‑inhibitor therapy even when eGFR declines below 30 mL/min/1.73 m²; the benefits in slowing disease progression outweigh the risks in advanced CKD. 1, 2

Avoidance of Dual/Triple RAAS Blockade

• Do not combine an ACE‑inhibitor with an angiotensin‑receptor blocker (ARB) or a direct renin inhibitor, as this raises the risk of hyper‑kalemia and acute kidney injury without added clinical benefit. 1, 2
• The triple combination of an ACE‑inhibitor, an ARB, and a mineralocorticoid‑receptor antagonist is discouraged. 3, 5

Interpretation of Creatinine Elevations

• Elevations in serum creatinine up to 30 % after ACE‑inhibitor initiation should be recognized as a therapeutic hemodynamic effect, not as acute kidney injury. 4

ACE Inhibitor/ARB Discontinuation Based on GFR

Introduction to ACE/ARB Management

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend continuing ACE inhibitors or ARBs even when eGFR falls below 30 mL/min/1.73 m², with consideration for dose reduction or discontinuation only at eGFR <15 mL/min/1.73 m² if specific complications develop, such as symptomatic hypotension, uncontrolled hyperkalemia, or uremic symptoms 6, 7

Continue ACE/ARB Through Advanced CKD

• The 2024 KDIGO guidelines explicitly state to continue ACE inhibitors or ARBs even when eGFR falls below 30 mL/min/1.73 m², as the benefits of these medications outweigh the risks in patients with advanced chronic kidney disease (CKD) 6, 7

Specific Threshold for Consideration of Discontinuation

• Consider reducing dose or discontinuing ACE/ARB only when eGFR <15 mL/min/1.73 m² and one of the following conditions is present: symptomatic hypotension, uncontrolled hyperkalemia despite medical treatment, or uremic symptoms requiring palliation, according to the Kidney International guidelines 6, 7, 8, 9

Acceptable Creatinine Rise After Initiation

• Continue ACE/ARB therapy unless serum creatinine rises by more than 30% within 4 weeks of starting or increasing the dose, as recommended by the Kidney International and Diabetes Care guidelines 6, 7, 9, 10
• A creatinine rise up to 30% reflects the desired hemodynamic effect of reducing intraglomerular pressure and is not acute kidney injury, as demonstrated by the ACCORD-BP trial 10

Managing Hyperkalemia Without Stopping ACE/ARB

• Hyperkalemia should be managed with potassium-lowering measures, such as moderate dietary potassium intake, diuretics, sodium bicarbonate supplementation, and gastrointestinal cation exchangers, rather than immediately stopping the ACE/ARB, according to the Kidney International guidelines 6, 7, 9, 10

Monitoring Protocol

• Check serum creatinine and potassium within 2-4 weeks after initiation or any dose increase, with earlier monitoring (within 1 week) recommended for patients with baseline eGFR <30 mL/min/1.73 m² or potassium >4.5 mEq/L, as advised by the Kidney International guidelines 6, 7, 9

Dosing Strategy in Advanced CKD

• Use the highest approved dose of ACE/ARB that is tolerated, even in advanced CKD, because proven benefits in clinical trials were achieved at target doses, according to the Kidney International guidelines 6, 7, 9
• There is no serum creatinine level that contraindicates ACE/ARB use, as stated by the Circulation guidelines 11